OCD Trial, Recruiting NCT02377375 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: OCD
Back to Ocd

OCD Trial, Recruiting

NCT02377375
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Obsessive-Compulsive Disorder (OCD) according to a standard medical diagnostic system (DSM-IV).
  • People who have tried medication treatments for OCD following the recommended treatment steps, without getting adequate relief.
  • People who have tried a structured talking therapy called Cognitive Behavioural Therapy (CBT) for OCD, without getting adequate relief.
  • People who have had OCD for at least 5 years.
  • People whose OCD symptoms score at least 30 out of 40 on a standard OCD severity scale called the Y-BOCS (confirm with trial site).
  • People aged between 20 and 65 years.

Who may not be able to join:

  • People who have been diagnosed with a severe personality disorder of a certain type (cluster A or B under DSM-IV), particularly where there may be a higher risk of impulsive or acting-out behaviour.
  • People who have been diagnosed with a brain condition caused by a physical or organic cause, or who have significant abnormal findings on a brain MRI scan.
  • People who currently have, or have had in the past, symptoms of psychosis (such as hallucinations or delusions).
  • People who are currently misusing substances such as drugs or alcohol, or whose recovery from past substance misuse is considered unstable (meaning they have not been free from substance misuse for at least the last 12 months).
  • People who have any condition affecting thinking and mental processing, other than motor tics or Tourette's Syndrome.
  • People who have an intellectual disability, as a minimum level of cognitive ability is needed to complete questionnaires and assessments during the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bart Nuttin, MD, PHD, UZ Leuven

Phone: 003216340859

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 January 2015
Est. completion
1 December 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Millimeter difference in position between planned and actual target

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov